Drink tablets have been checked out of business copy the bottom of the big alligator came to the market to change the day!

Since this year, as of July 9, the State Administration of Food and Drug Administration issued a total of 10 times involving 384 batches of Chinese medicine tablets unqualified announcement, and at the same time, it is understood that in addition to Kangmei Pharmaceuticals, Tongrentang and other Chinese medicine giants that have already carried out the layout, other listed companies in the pharmaceutical industry have also launched a circle.Fly inspection efforts to increase
July 6, according to the State Administration of Food and Drug Administration released information, by the China Food and Drug Inspection Research Institute inspection, marked as Jilin Province Yuanli Pharmaceutical Co., Ltd., Anhui Baiyitang Chinese medicine tablets Co., Ltd., Shaoyang Shennon Chinese Medicine Technology Development Co., Ltd., Chongqing Kandi Pharmaceutical Co., Ltd. and other enterprises The production of 9 batches of geese do not eat grass unqualified, unqualified items for impurities, marked as Anhui Luzhou Zhejiang Zhejiang Chinese medicine tablets Co. , Ltd. production of 1 batch of fat sea unqualified, unqualified items for aflatoxin, marked as Guangxi Zhang Yitang Chinese medicine tablets Co. , Ltd. production of 2 batches of jaundice unqualified, unqualified items for the trait.
The State Administration of Food and Drug Administration said that for the above-mentioned non-conforming Chinese medicine tablets, the relevant provincial (district, city) Food and Drug Administration has taken seizure and other control measures, requiring enterprises to suspend the sale of the use, recall products, and carry out rectification.
The State Administration of Food and Drug Administration requires the Food and Drug Administration of the province (district or city) where the production enterprises are located to investigate the illegal acts of producing and selling unqualified drugs in accordance with the relevant laws, and to disclose the results of the treatment of enterprises or units related to the production and sale of unqualified drugs within three months, and to report the relevant situation in a timely manner.
quality of Chinese medicine tablets has been one of the focus of social attention, in the past two years, the state has increased the Chinese medicine and Chinese medicine drink tablets link of the flight inspection efforts.
according to reporter statistics, the reasons for the non-conformity of Chinese medicine tablets also include sulfur dioxide residues, non-volatiles and acid insoluble ash under inspection, total ash and so on.
, according to reporters combing, in the past by the State Administration of Food and Drug Administration named the production of Chinese medicine tablets companies, including Yunnan white medicine, including some well-known enterprises.chinese medicine tablets ushered in a golden period of development?
, while the state has stepped up supervision of Chinese medicine tablets, Chinese medicine tablets are also considered to have ushered in a "golden period of development."
" countries to increase the intensity of flight inspection, this market gradually standardized. However, the supply of quality products is relatively small and prices will rise relatively. "An industry source told reporters that high quality and good prices will become a big trend. In addition, the policy dividend will also promote the development and growth of Chinese medicine tablets.
2016, the 13th Five-Year Plan for the Development of Traditional Chinese Medicine was released, and the Chinese medicine industry was included as a pillar industry of the national economy for the first time. On July 1, 2017, the Chinese Medicine Law was implemented, which helped to promote the development of the Chinese medicine industry.
, with the gradual progress of national medical reform, the market for Chinese medicine tablets is expected to open further.
It is understood that in May 2015, the General Office of the State Council issued the "Guidelines on the Pilot Of the Comprehensive Reform of Urban Public Hospitals", and all public hospitals in the pilot cities promoted the separation of medicines, actively explored various effective ways to reform the mechanism for supplementing medicines with medicines, eliminated the drug increase (except for Chinese medicine tablets), and strived to reduce the proportion of medicines (excluding Chinese medicine tablets) in public hospitals in pilot cities to about 30% by 2017.
means that Chinese medicine tablets are not within the scope of policy implications, whether by eliminating drug additions or reducing the proportion of medicines.
analysis from Guangzhou Hang Seng shows that with the full roll-out of the zero-plus policy, the use of Chinese medicine tablets in hospitals will increase significantly.
2016, the market size of Chinese medicine tablets was 195.6 billion yuan, and the overall market size of Chinese pharmaceutical tablets in 2017 is expected to reach 233 billion yuan, up 19% YoY, while the overall market size of Chinese pharmaceutical tablets in 2018 is 273.4 billion yuan, up 17% YoY.
, however, in the third-party pharmaceutical service platform McConley founder Shi Lichen, this is considered that the Chinese medicine tablet industry ushered in an inflection point in performance is too early.
" At present, the main sales channels of Chinese medicine tablets are hospitals and clinics, however, most of the three hospitals have more Western medicine, the actual prescription of Chinese medicine tablets is not a lot, in addition, most Chinese hospitals are less profitable." Chinese medicine tablets industry is generally small in size, the policy environment and sales structure has not changed substantially, sales are difficult to rise significantly. listed companies to accelerate the layout of Chinese medicine tablets
analysts believe that the country is paying more and more attention to the development of the Chinese medicine industry, so the Chinese medicine drink tablets industry supervision is also growing.
recent years, Chinese medicine drink tablets have repeatedly made the black list of quality. In the future, under the influence of the policy of continuous tightening of state regulation, some less competitive small enterprises will be eliminated and the concentration of the industry will be further enhanced.
understood that, in addition to Kangmei Pharmaceuticals, Tongrentang and other Chinese medicine giants that have already carried out the layout, other listed companies in the pharmaceutical industry have also launched a circle.
On June 27 this year, Tianming Pharmaceuticals announced that it intends to purchase 100% of dechang Pharmaceuticals held by Geddes and Sun Wei for a total of 360 million yuan, that the owner's business of Dechang Pharmaceuticals is the production and sale of Chinese medicine tablets, and that the production line in which Dechang Pharmaceuticals is in production was certified by GMP in 2015 and 2016, respectively. As a performance compensation obligator, Geddes committed to Dechang Pharmaceuticals' audited net profit after deducting non-recurring gains and losses in 2017, 2018 and 2019 of not less than 39.5 million yuan, 44.2 million yuan and 48.6 million yuan, respectively.
January 17 this year, A-share listed company Ruikang Pharmaceuticals intends to subscribe for 20.82 million shares issued by jingquan Pharmaceuticals, a new three-board listed company, at a price of 5.28 yuan per share. Jingquan Chinese medicine is a company engaged in the production and sale of Chinese medicine tablets, the fund raised 110 million yuan, of which 3995.72 million yuan to pay for the "annual output of 10,000 tons of Chinese medicine tablets, extracts, Chinese medicine health care products project" decoration and purchase of supporting facilities. At the end of
, China New Pharmaceutical Co., Ltd. issued the "Announcement on the Acquisition of 100% Equity in Tianjin Chinese Medicine Tablet Co., Ltd. and the signing of the equity transfer agreement", China New Pharmaceuticals said that the company's development strategy is to "rely on the core business of Chinese medicine upstream and downstream extension, around the main industry to expand into related areas, to do a long-term real industrial chain." The Chinese medicine tablet industry is one of the three pillars of the Chinese medicine industry, which plays an important role in the industrial chain, and the transaction is in line with the company's strategic development ideas. (Securities Daily)